Herman et al. demonstrated dose- and time-dependent cytotoxicity of ibrutinib in chronic lymphocytic leukemia (CLL) via an apoptotic pathway dependent on caspase-3 [26]. The gene discussed is CASP3; the disease is B-cell chronic lymphocytic leukemia.